BioVie (BIVI) Competitors $1.19 +0.08 (+7.21%) Closing price 06/12/2025 04:00 PM EasternExtended Trading$1.18 -0.01 (-0.84%) As of 08:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. IMUX, SNTI, OCX, CLLS, FBRX, PDSB, IMRX, ELUT, IGMS, and EPIXShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Immunic (IMUX), Senti Biosciences (SNTI), OncoCyte (OCX), Cellectis (CLLS), Forte Biosciences (FBRX), PDS Biotechnology (PDSB), Immuneering (IMRX), Elutia (ELUT), IGM Biosciences (IGMS), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Its Competitors Immunic Senti Biosciences OncoCyte Cellectis Forte Biosciences PDS Biotechnology Immuneering Elutia IGM Biosciences ESSA Pharma Immunic (NASDAQ:IMUX) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Does the MarketBeat Community believe in IMUX or BIVI? Immunic received 97 more outperform votes than BioVie when rated by MarketBeat users. However, 66.67% of users gave BioVie an outperform vote while only 66.09% of users gave Immunic an outperform vote. CompanyUnderperformOutperformImmunicOutperform Votes11566.09% Underperform Votes5933.91% BioVieOutperform Votes1866.67% Underperform Votes933.33% Do analysts recommend IMUX or BIVI? Immunic presently has a consensus price target of $11.60, indicating a potential upside of 1,274.57%. BioVie has a consensus price target of $3.00, indicating a potential upside of 152.10%. Given Immunic's higher probable upside, analysts plainly believe Immunic is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25BioVie 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals believe in IMUX or BIVI? 51.8% of Immunic shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 3.0% of Immunic shares are owned by company insiders. Comparatively, 4.0% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has preferable earnings & valuation, IMUX or BIVI? Immunic is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$93.61M-$1.23-0.69BioVieN/AN/A-$32.12M-$7.91-0.15 Is IMUX or BIVI more profitable? BioVie's return on equity of -134.07% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -169.55% -118.96% BioVie N/A -134.07%-93.44% Does the media refer more to IMUX or BIVI? In the previous week, Immunic had 9 more articles in the media than BioVie. MarketBeat recorded 10 mentions for Immunic and 1 mentions for BioVie. BioVie's average media sentiment score of 1.89 beat Immunic's score of 0.96 indicating that BioVie is being referred to more favorably in the news media. Company Overall Sentiment Immunic Positive BioVie Very Positive Which has more volatility and risk, IMUX or BIVI? Immunic has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, BioVie has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. SummaryImmunic and BioVie tied by winning 8 of the 16 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioViePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.10M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-0.128.6727.1419.96Price / SalesN/A262.53416.10157.63Price / CashN/A65.8538.2534.64Price / Book0.476.597.074.69Net Income-$32.12M$143.75M$3.23B$248.14M7 Day Performance10.19%0.68%0.71%0.91%1 Month Performance11.21%11.93%9.65%5.71%1 Year Performance144.76%4.33%32.07%14.71% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie2.4928 of 5 stars$1.19+7.2%$3.00+152.1%+142.1%$22.10MN/A-0.1210IMUXImmunic3.2419 of 5 stars$0.87+10.0%$11.60+1,237.5%-33.0%$83.10MN/A-0.7170Short Interest ↑High Trading VolumeSNTISenti Biosciences2.3962 of 5 stars$3.12-18.8%$8.50+172.4%+5.9%$81.37M$2.56M-0.204Analyst ForecastGap UpOCXOncoCyte2.8353 of 5 stars$2.78-6.4%$6.06+118.1%-1.8%$79.51M$3.84M-0.79120Positive NewsCLLSCellectis3.5099 of 5 stars$1.43+1.1%$7.00+391.2%-43.5%$79.21M$47.63M-1.10290Gap DownFBRXForte Biosciences3.0616 of 5 stars$11.95+5.6%$61.00+410.5%+54,900.0%$78.67MN/A-0.735Options VolumeGap UpPDSBPDS Biotechnology1.5882 of 5 stars$1.71+1.2%$9.00+426.3%-38.9%$78.16MN/A-1.4720Analyst ForecastAnalyst RevisionIMRXImmuneering2.9808 of 5 stars$2.17+1.9%$14.33+560.5%+27.3%$78.09M$320K-1.1060News CoverageShort Interest ↑ELUTElutia3.8648 of 5 stars$1.89-0.5%$8.00+323.3%-50.3%$77.71M$23.71M-0.72180Analyst RevisionIGMSIGM Biosciences4.4283 of 5 stars$1.29-2.3%$5.50+326.4%-85.0%$77.11M$2.68M-0.35190EPIXESSA Pharma2.029 of 5 stars$1.70-0.6%$2.00+17.6%-67.3%$75.46MN/A-2.4650Positive News Related Companies and Tools Related Companies Immunic Competitors Senti Biosciences Competitors OncoCyte Competitors Cellectis Competitors Forte Biosciences Competitors PDS Biotechnology Competitors Immuneering Competitors Elutia Competitors IGM Biosciences Competitors ESSA Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIVI Stock Free BIVI Stock Alerts